Core Insights - Medtronic reported revenue of $8.96 billion for the quarter ended October 2025, reflecting a year-over-year increase of 6.6% and surpassing the Zacks Consensus Estimate of $8.86 billion by 1.11% [1] - The company's EPS for the quarter was $1.36, up from $1.26 in the same quarter last year, exceeding the consensus estimate of $1.31 by 3.82% [1] Revenue Breakdown - U.S. Revenue: $4.52 billion, slightly below the average estimate of $4.53 billion, with a year-over-year increase of 4.9% [4] - International Revenue: $4.45 billion, exceeding the average estimate of $4.33 billion [4] - Cardiovascular - Structural Heart & Aortic: $566 million, above the estimate of $548.63 million, with a 15% year-over-year increase [4] - Cardiovascular - Cardiac Rhythm & Heart Failure: $905 million, surpassing the estimate of $866.81 million [4] - Worldwide Cardiovascular Revenue: $3.44 billion, exceeding the estimate of $3.37 billion, with a 10.8% year-over-year increase [4] - Worldwide Diabetes Revenue: $757 million, above the estimate of $749.91 million, with a 10.4% year-over-year increase [4] - Worldwide Medical Surgical Revenue: $2.17 billion, below the average estimate of $2.37 billion, with a 2% year-over-year increase [4] - Worldwide Neuroscience Revenue: $2.56 billion, exceeding the estimate of $2.49 billion, with a 4.5% year-over-year increase [4] - Neuroscience - Neuromodulation: $520 million, above the estimate of $510.92 million, with an 8.3% year-over-year increase [4] - Neuroscience - Cranial & Spinal Technologies: $1.3 billion, matching the estimate, with a 5.3% year-over-year increase [4] - Cardiovascular - Coronary & Peripheral Vascular: $655 million, slightly below the estimate of $663.24 million, with a 1.9% year-over-year increase [4] Stock Performance - Medtronic's shares have returned +0.4% over the past month, outperforming the Zacks S&P 500 composite's +0.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - CNH Industrial reported a revenue of $4.4 billion for the quarter ended September 2025, reflecting a decline of 5.5% year-over-year, with EPS at $0.08 compared to $0.24 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $4.3 billion by 2.21%, while the EPS fell short of the consensus estimate of $0.13 by 38.46% [1] Revenue Performance - Agriculture Sales in North America were $1 billion, below the estimated $1.12 billion, marking a year-over-year decline of 28.7% [4] - Agriculture Sales in Europe, the Middle East, and Africa reached $1.05 billion, surpassing the average estimate of $908.39 million, with a year-over-year increase of 16% [4] - Agriculture Sales in South America totaled $513 million, below the average estimate of $553.48 million, representing an 11.9% decline year-over-year [4] - Construction Sales in Asia Pacific were $42 million, slightly above the estimated $40.74 million, with no change year-over-year [4] - Construction Sales in North America reached $400 million, exceeding the average estimate of $329.41 million, reflecting an 11.7% year-over-year increase [4] - Construction Sales in Europe, the Middle East, and Africa were $191 million, above the average estimate of $150.4 million, with a year-over-year increase of 26.5% [4] Overall Financial Metrics - Net Sales amounted to $3.7 billion, slightly above the estimated $3.65 billion, but down 7.4% year-over-year [4] - Finance, interest, and other income were reported at $697 million, exceeding the estimate of $660.15 million, with a year-over-year increase of 6.1% [4] - Total Industrial Activities in Construction generated $739 million, surpassing the average estimate of $654.61 million, reflecting a year-over-year increase of 7.6% [4] - Total Industrial Activities in Agriculture reported $2.96 billion, slightly below the average estimate of $2.97 billion, with a year-over-year decline of 10.5% [4] - Total Industrial Activities revenue was $3.74 billion, exceeding the estimate of $3.65 billion, but down 7.1% year-over-year [4] - Financial Services revenue reached $684 million, above the estimate of $659.22 million, with a year-over-year increase of 3.8% [4] Stock Performance - CNH shares have returned -2.2% over the past month, compared to a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - BILL Holdings reported revenue of $395.74 million for the quarter ended September 2025, reflecting a year-over-year increase of 10.4% and a surprise of +1.31% over the Zacks Consensus Estimate of $390.61 million [1] - The company's EPS was $0.61, slightly down from $0.63 in the same quarter last year, but exceeded the consensus estimate of $0.51 by +19.61% [1] Financial Performance Metrics - Total Payment Volume reached $89 billion, surpassing the average estimate of $87.94 billion [4] - The number of transactions processed was 33 million, which fell short of the estimated 33.96 million [4] - Revenue from interest on funds held for customers was $37.74 million, compared to the average estimate of $36.22 million, representing a year-over-year decline of -13.3% [4] - Revenue from subscription and transaction fees was $358.01 million, exceeding the average estimate of $354.03 million, with a year-over-year increase of +13.7% [4] - Subscription fees generated $70.8 million, above the average estimate of $68.77 million, while transaction fees accounted for $287.2 million, also surpassing the average estimate of $285.3 million [4] Stock Performance - Shares of BILL Holdings have declined by -10.8% over the past month, contrasting with the Zacks S&P 500 composite's increase of +1.3% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Viewpoint - ServiceNow's stock price has been stable recently, with investors concentrating on its revenue growth, but this may change with the upcoming third-quarter financial report [1] Group 1 - The stock price of ServiceNow has remained in a tight range over the past few weeks [1] - Investors are currently focused on the company's revenue growth [1] - Anticipation is building for the release of the third-quarter financial results, which could impact stock performance [1]

Core Insights - Tilray's stock price has experienced a significant bull run, emerging as one of the top-performing companies on Wall Street [1] - The stock surged from a low of $0.355 in June to a peak of $1.88, indicating a substantial increase in value [1] Company Performance - The notable increase in Tilray's stock price reflects strong investor interest and market confidence in the company's future prospects [1] - The performance trajectory suggests a positive sentiment surrounding the cannabis industry, particularly for companies like Tilray that are positioned for growth [1]

Core Points - Amazon.com Inc. (NASDAQ: AMZN) shares experienced a decline of 5.56% over the last five trading sessions, following a previous loss of 1.32% in the five sessions prior, resulting in a year-to-date gain of only 0.22% [1]

Core Insights - Abbott reported revenue of $11.14 billion for the quarter ended June 2025, reflecting a 7.4% increase year-over-year and a surprise of +0.63% over the Zacks Consensus Estimate of $11.07 billion [1] - The earnings per share (EPS) was $1.26, up from $1.14 in the same quarter last year, with an EPS surprise of +0.8% compared to the consensus estimate of $1.25 [1] Financial Performance Metrics - Net sales in Diagnostics (U.S.) were $811 million, slightly below the average estimate of $832.19 million, showing a year-over-year change of -0.1% [4] - International Nutrition net sales were $1.26 billion, matching the average estimate and reflecting a year-over-year increase of +3.1% [4] - U.S. Nutrition net sales reached $957 million, below the average estimate of $985.2 million, with a year-over-year increase of +2.6% [4] - International Diagnostics net sales were $1.36 billion, slightly below the average estimate of $1.38 billion, showing a year-over-year decline of -1.5% [4] - Established Pharmaceuticals net sales were $1.38 billion, exceeding the average estimate of $1.37 billion, with a year-over-year increase of +6.9% [4] - Total Diagnostics net sales were $2.17 billion, below the average estimate of $2.22 billion, reflecting a year-over-year change of -1% [4] - Medical Devices in Diabetes Care reported net sales of $1.98 billion, surpassing the average estimate of $1.94 billion, with a significant year-over-year increase of +20.2% [4] - Total Nutrition net sales were $2.21 billion, slightly below the average estimate of $2.24 billion, with a year-over-year increase of +2.9% [4] - Medical Devices in Structural Heart reported net sales of $636 million, below the average estimate of $643.65 million, with a year-over-year increase of +12.8% [4] - Heart Failure Medical Devices net sales were $368 million, exceeding the average estimate of $350.99 million, reflecting a year-over-year increase of +14.6% [4] - Electrophysiology Medical Devices net sales reached $700 million, surpassing the average estimate of $671.21 million, with a year-over-year increase of +11.6% [4] - Vascular Medical Devices net sales were $757 million, slightly above the average estimate of $754.03 million, with a year-over-year increase of +4.6% [4] Stock Performance - Abbott's shares have returned -0.5% over the past month, while the Zacks S&P 500 composite has increased by +4.2% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]